Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $8.40
Latest analyst grade actions
1254 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-22
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 40.38 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 97.39 | Oscillator | Sell |
| Williams %R (14) | -7.84 | Oscillator | Sell |
| MACD (12, 26, 9) | -0.15 (Hist 0.05) | Oscillator | Buy |
| Average Directional Index (14) | 34.37 (+DI 36.9 / -DI 57.8) | Trend | Strong Sell |
| EMA 20 | 8.47 | MA | Sell |
| SMA 20 | 8.38 | MA | Buy |
| EMA 50 | 8.73 | MA | Strong Sell |
| SMA 50 | 8.89 | MA | Strong Sell |
| SMA 200 | 8.52 | MA | Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
SEC EDGAR filings · last 12 months
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
Central Garden and Pet (NASDAQ: CENTA - Get Free Report) and KP Tissue (OTCMKTS:KPTSF - Get Free Report) are both consumer staples companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings. Insider and Institutional Ownership 50.8%
KP Tissue TSE: KPT reported higher second-quarter revenue and adjusted EBITDA, supported by stronger U.S. sales volumes, improved performance at its Memphis facility and lower pulp prices. Management said it expects third-quarter adjusted EBITDA to remain in line with the CAD 90.6 million generated in the second quarter.
KP Tissue Inc. (KPT:CA) Q2 2026 Earnings Call Transcript
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | 0.19 | 1.31 | Beat 606.6% | $387.8M |
| May 14, 2026 | 0.17 | 0.16 | Miss -4.4% | $391.6M |
| Feb 18, 2026 | 0.18 | 0.44 | Beat 141.2% | $407.8M |
| Nov 13, 2025 | 0.10 | 0.60 | Beat 482.5% | $402.9M |
| Aug 13, 2025 | 0.09 | -1.00 | Miss -1222.3% | $393.8M |
| May 14, 2025 | 0.06 | 0.09 | Beat 52.2% | $379.5M |
TTM vs. 5-year historical average (annual ratios)
| Metric | KPTSF | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 13.1x | 19.3x · sector 38.2x | Discount |
| Forward P/E | — | — | n/a |
| Price / Book | 1.6x | 1.3x | Elevated |
| Price / Sales | — | — | n/a |
| EV / EBITDA | 0.7x | 0.5x | Elevated |
| Return on equity | 12.8% | — | Healthy |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.00 | 0.00 | Conservative |
| Piotroski / Altman Z | 2/9 | Z 31.49 | Safe zone |
Discounted cash flow model